$IRRX
INTEGRATED RAIL & RESOURCES ACQUISITION CORP Stock $irrx

$irrx Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-Q Financial Statement

#000121390025003482 Filed on January 14, 2025

Income Statement

Concept	2025 Q1	2024 Q3	2023 Q4
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$405.1K	$347.3K
YoY Change		47.96%	-66.39%
Operating Profit		-$405.1K
YoY Change		47.97%
Interest Expense			$892.3K
YoY Change			-26.27%
% of Operating Profit
Other Income/Expense, Net		$537.4K	$3.135M
YoY Change		-86.53%	-465.81%
Pretax Income		$132.4K	$3.680M
YoY Change		-96.44%	1978.86%
Income Tax		$111.3K	$162.8K
% Of Pretax Income		84.11%	4.42%
Net Earnings		$21.04K	$3.517M
YoY Change		-99.4%	-1526.24%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share			$0.29
COMMON SHARES
Basic Shares Outstanding	6.000M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$190.00
YoY Change		-99.65%
Cash & Equivalents	$426.00	$189.00
Short-Term Investments
Other Short-Term Assets		$33.59K
YoY Change		-92.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.12K	$33.78K
YoY Change	-85.21%	-93.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$72.73M
YoY Change		-69.38%
Other Assets
YoY Change
Total Long-Term Assets	$23.76M	$72.73M
YoY Change	-66.74%	-69.38%
TOTAL ASSETS
Total Short-Term Assets	$14.12K	$33.78K
Total Long-Term Assets	$23.76M	$72.73M
Total Assets	$23.77M	$72.77M
YoY Change	-66.76%	-69.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$0.00
YoY Change		-100.0%
Accrued Expenses		$700.7K
YoY Change		17.32%
Deferred Revenue
YoY Change
Short-Term Debt		$5.471M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.47M	$9.271M
YoY Change	36.93%	747.23%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$10.14M
YoY Change		-7.62%
Total Long-Term Liabilities		$10.14M
YoY Change		-7.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.47M	$9.271M
Total Long-Term Liabilities		$10.14M
Total Liabilities	$20.36M	$19.41M
YoY Change	-6.08%	57.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.87M	-$18.12M
YoY Change	-8.13%	58.53%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$18.87M	-$18.12M
YoY Change
Total Liabilities & Shareholders Equity	$23.77M	$72.77M
YoY Change	-66.76%	-69.43%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	$21.04K	$3.517M
YoY Change	-99.4%	-1526.24%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$108.7K
YoY Change		-59.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$420.0K
YoY Change		-81.48%
Cash From Investing Activities		-$420.0K
YoY Change		-81.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		520.8K
YoY Change		-77.36%
NET CHANGE
Cash From Operating Activities		-108.7K
Cash From Investing Activities		-420.0K
Cash From Financing Activities		520.8K
Net Change In Cash		-7.890K
YoY Change		-96.68%
FREE CASH FLOW
Cash From Operating Activities		-$108.7K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41048
	dei	Entity Registrant Name EntityRegistrantName	INTEGRATED RAIL AND RESOURCES ACQUISITION CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2581754
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 W. Morse Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
	dei	Entity Address City Or Town EntityAddressCityOrTown	Winter Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32789
	dei	City Area Code CityAreaCode	(321)
	dei	Local Phone Number LocalPhoneNumber	972-1583
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5999659	shares
CY2024Q3	us-gaap	Cash Cash	426	usd
CY2023Q4	us-gaap	Cash Cash	189	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13697	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33590	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	14123	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	33779	usd
CY2024Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	23755380	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	72731536	usd
CY2024Q3	us-gaap	Assets Assets	23769503	usd
CY2023Q4	us-gaap	Assets Assets	72765315	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1025357	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	700664	usd
CY2024Q3	irrx	Accrued Franchise Tax AccruedFranchiseTax	102571	usd
CY2023Q4	irrx	Accrued Franchise Tax AccruedFranchiseTax	80000	usd
CY2024Q3	irrx	Accrued Excise Tax AccruedExciseTax	2251177	usd
CY2023Q4	irrx	Accrued Excise Tax AccruedExciseTax	1741420	usd
CY2024Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1541373	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1177040	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11473118	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9271054	usd
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	836000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2090000	usd
CY2024Q3	irrx	Deferred Underwriting Fee Payable Noncurrent DeferredUnderwritingFeePayableNoncurrent	8050000	usd
CY2023Q4	irrx	Deferred Underwriting Fee Payable Noncurrent DeferredUnderwritingFeePayableNoncurrent	8050000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	20359118	usd
CY2023Q4	us-gaap	Liabilities Liabilities	19411054	usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	22277709	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	71474496	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18867899	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18120810	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-18867324	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-18120235	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23769503	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72765315	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	405080	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	273767	usd
	us-gaap	Operating Expenses OperatingExpenses	890887	usd
	us-gaap	Operating Expenses OperatingExpenses	1044323	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-405080	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-273767	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-890887	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1044323	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	328437	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1298862	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1274699	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4110737	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-234153	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	114175	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-209000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2926000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1254000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2299000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	537437	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3990709	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2528699	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1925912	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	132357	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3716942	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1637812	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	881589	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	111320	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	213088	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	364333	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	855721	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	21037	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	3503854	usd
	us-gaap	Net Income Loss NetIncomeLoss	1273479	usd
	us-gaap	Net Income Loss NetIncomeLoss	25868	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-18120235	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-509757	usd
CY2024Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	791449	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2292526	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-17128915	usd
CY2024Q2	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	337231	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1040084	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-18506230	usd
CY2024Q3	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	382131	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	21037	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-18867324	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11430185	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2413318	usd
CY2023Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	1409451	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-944891	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-16197845	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1064668	usd
CY2023Q2	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	4208890	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-21471403	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	3503854	usd
CY2023Q3	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	1773823	usd
CY2023Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-796529	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-20537901	usd
	us-gaap	Net Income Loss NetIncomeLoss	1273479	usd
	us-gaap	Net Income Loss NetIncomeLoss	25868	usd
	irrx	Reinvested Dividends On Funds Held In Trust Account ReinvestedDividendsOnFundsHeldInTrustAccount	560256	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	114175	usd
	irrx	Payment Of Transfer Of Funds Held In Trust Account For Payment Of Taxes PaymentOfTransferOfFundsHeldInTrustAccountForPaymentOfTaxes	3550481	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1274695	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-236249	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1254000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2299000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	364333	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	648448	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-19893	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-346193	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	324693	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-115952	usd
	irrx	Increase Decrease In Accrued Franchise Tax IncreaseDecreaseInAccruedFranchiseTax	22571	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-523726	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1298289	usd
	irrx	Increase Decrease In Accrued Franchise Tax IncreaseDecreaseInAccruedFranchiseTax	-40685	usd
	irrx	Proceeds From Cash Withdrawn From Trust Account To Pay Franchise And Income Taxes ProceedsFromCashWithdrawnFromTrustAccountToPayFranchiseAndIncomeTaxes	83253	usd
	irrx	Proceeds From Cash Withdrawn From Trust Account To Pay Franchise And Income Taxes ProceedsFromCashWithdrawnFromTrustAccountToPayFranchiseAndIncomeTaxes	634257	usd
	irrx	Paymentto Cash Deposited Into Trust Account PaymenttoCashDepositedIntoTrustAccount	540000	usd
	irrx	Paymentto Cash Deposited Into Trust Account PaymenttoCashDepositedIntoTrustAccount	4433225	usd
	irrx	Proceeds From Cash Withdrawn From Trust Account For Payment To Redeeming Stockholders ProceedsFromCashWithdrawnFromTrustAccountForPaymentToRedeemingStockholders	50707598	usd
	irrx	Proceeds From Cash Withdrawn From Trust Account For Payment To Redeeming Stockholders ProceedsFromCashWithdrawnFromTrustAccountForPaymentToRedeemingStockholders	174141949	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50250851	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	170342981	usd
	irrx	Net Interest To Pay Dissolution Expenses NetInterestToPayDissolutionExpenses	100000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	540000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4433225	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	440710	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	600000	usd
	irrx	Proceeds From Working Capital Loan Related Party ProceedsFromWorkingCapitalLoanRelatedParty	17935	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50707598	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	174141949	usd
CY2024Q3	irrx	Percentage Fair Market Value PercentageFairMarketValue	0.80	pure
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-49726888	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-169090789	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	237	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-46097	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	189	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54173	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	426	usd
CY2024Q3	irrx	Percentage Of Outstanding Voting Securities PercentageOfOutstandingVotingSecurities	0.50	pure
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8076	usd
	irrx	Remeasurement Of Common Stock Subject To Redemption RemeasurementOfCommonStockSubjectToRedemption	1510811	usd
CY2021Q4	irrx	Term Of Restricted Investments TermOfRestrictedInvestments	P185D
CY2024Q3	irrx	Minimum Net Tangible Assets Upon Consummation Of Business Combination MinimumNetTangibleAssetsUponConsummationOfBusinessCombination	5000001	usd
	irrx	Remeasurement Of Common Stock Subject To Redemption RemeasurementOfCommonStockSubjectToRedemption	7392164	usd
	irrx	Accrued Excise Tax On Common Stock Redemptions AccruedExciseTaxOnCommonStockRedemptions	509757	usd
	irrx	Accrued Excise Tax On Common Stock Redemptions AccruedExciseTaxOnCommonStockRedemptions	1741420	usd
CY2024Q3	irrx	Percentage Of Public Shareholding To Be Redeemed In Case Of Non Occurrence Of Business Combination PercentageOfPublicShareholdingToBeRedeemedInCaseOfNonOccurrenceOfBusinessCombination	1	pure
CY2024Q3	irrx	Percentage Of The Public Shares Redeemable In Case Business Combination Is Not Consummated PercentageOfThePublicSharesRedeemableInCaseBusinessCombinationIsNotConsummated	1	pure
CY2024Q3	us-gaap	Share Price SharePrice	10.1
	irrx	Threshold Period From The Closing Of Initial Public Offering To Consummate An Initial Business Combination ThresholdPeriodFromTheClosingOfInitialPublicOfferingToConsummateAnInitialBusinessCombination	P12M
	irrx	Number Of Months Extended To Consummate A Business Combination For Each Time NumberOfMonthsExtendedToConsummateABusinessCombinationForEachTime	P3M
	irrx	Total Period Including Extended From The Closing Of Initial Public Offering To Consummate An Initial Business Combination TotalPeriodIncludingExtendedFromTheClosingOfInitialPublicOfferingToConsummateAnInitialBusinessCombination	P18M
CY2024Q3	irrx	Per Unit Amount To Be Maintained In Trust Account PerUnitAmountToBeMaintainedInTrustAccount	0.1
CY2024Q3	irrx	Per Share Amount Elected In The Event Of Period Extension PerShareAmountElectedInTheEventOfPeriodExtension	10.3
CY2023Q1	us-gaap	Assets Held In Trust AssetsHeldInTrust	94489075	usd
CY2023Q1	irrx	Cash Withdrawn From Trust Account Per Share For Payment To Redeeming Stockholders CashWithdrawnFromTrustAccountPerShareForPaymentToRedeemingStockholders	10.32
CY2024Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	79652874	usd
	irrx	Cash Withdrawn From Trust Account Per Share For Payment To Redeeming Stockholders CashWithdrawnFromTrustAccountPerShareForPaymentToRedeemingStockholders	10.83
CY2024Q1	irrx	Commitment To Contribute Additional Funds Into The Trust Account CommitmentToContributeAdditionalFundsIntoTheTrustAccount	50000	usd
CY2024Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	395138	usd
CY2024Q1	irrx	Cash Withdrawn From Trust Account Per Share For Payment To Redeeming Stockholders CashWithdrawnFromTrustAccountPerShareForPaymentToRedeemingStockholders	0.09
CY2024Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	395138	usd
CY2022Q4	us-gaap	Deposits Deposits	5543225	usd
CY2024Q1	irrx	Aggregate Global Market Capitalization Amount AggregateGlobalMarketCapitalizationAmount	40000000	usd
CY2024Q3	irrx	Threshold Minimum Cash To Remain Available On Closing Of Business Combination ThresholdMinimumCashToRemainAvailableOnClosingOfBusinessCombination	44000000	usd
	irrx	Agreement Initial Term AgreementInitialTerm	P10Y
	us-gaap	Line Of Credit Facility Frequency Of Commitment Fee Payment LineOfCreditFacilityFrequencyOfCommitmentFeePayment	the Facility obtaining and maintaining the nameplate capacity for the period required to process 500,000 barrels in a 60-day time frame (the “Nameplate Capacity”), or approximately 15,000 barrels of crude feedstocks per day;
CY2024Q3	us-gaap	Significant Supply Commitment Remaining Minimum Amount Committed SignificantSupplyCommitmentRemainingMinimumAmountCommitted	50000	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basis of Presentation</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted pursuant to the rules and regulation of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the period presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Accompanying unaudited statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on April 17, 2024 which contains the audited financial statements and notes thereto.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ended December 31, 2024 or for any future interim periods.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Use of Estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of Credit Risk</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20900000	shares
	irrx	Dissolution Expense DissolutionExpense	100000	usd
CY2024Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.841	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.222	pure
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.057	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.971	pure
CY2024Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q3	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	163845	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	163845	usd
CY2022Q3	irrx	Excise Tax Rate ExciseTaxRate	0.01	pure
CY2022Q3	irrx	Accrued Excise Tax AccruedExciseTax	2251177	usd
CY2023Q4	irrx	Accrued Excise Tax AccruedExciseTax	1741420	usd
CY2024Q4	irrx	Estimated Interest Rate EstimatedInterestRate	0.10	pure
CY2024Q4	irrx	Underpayment Penalty Percentage UnderpaymentPenaltyPercentage	0.05	pure
CY2024Q4	irrx	Total Liability Percentage TotalLiabilityPercentage	0.25	pure
CY2024Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	23755380	usd
CY2024Q3	us-gaap	Deposits Deposits	150000	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	72731536	usd
CY2023	irrx	Withdrew Of Interest Earned In The Trust Account WithdrewOfInterestEarnedInTheTrustAccount	634257	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	667250	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	667250	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.63
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.8
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74637	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74637	usd
	irrx	Reinvested Dividends On Funds Held In Trust Account ReinvestedDividendsOnFundsHeldInTrustAccount		usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.49
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.49
	irrx	Payment Of Transfer Of Funds Held In Trust Account For Payment Of Taxes PaymentOfTransferOfFundsHeldInTrustAccountForPaymentOfTaxes		usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	irrx	Proceeds From Working Capital Loan Related Party ProceedsFromWorkingCapitalLoanRelatedParty		usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue		usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001854795
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1500000	usd
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	750000	usd
CY2024Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	355000	shares
CY2024Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	3900000	usd
CY2024Q3	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	30000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	90000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	90000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	0	usd
	irrx	Underwriting Discount Per Unit UnderwritingDiscountPerUnit	0.2
	irrx	Underwriting Discount Value UnderwritingDiscountValue	4600000	usd
	irrx	Underwriting Additional Fee Per Unit UnderwritingAdditionalFeePerUnit	0.35
CY2024Q3	irrx	Deferred Underwriting Fee Payable Noncurrent DeferredUnderwritingFeePayableNoncurrent	8050000.00	usd
	irrx	Number Of Days From Which Warrants Become Exercisable After The Completion Of A Business Combination NumberOfDaysFromWhichWarrantsBecomeExercisableAfterTheCompletionOfABusinessCombination	P30D
	irrx	Threshold Business Days After The Closing Of Business Combination Make Efforts To File With Sec For Effective Registration ThresholdBusinessDaysAfterTheClosingOfBusinessCombinationMakeEffortsToFileWithSecForEffectiveRegistration	P20D
	us-gaap	Noninterest Expense Investment Advisory Fees NoninterestExpenseInvestmentAdvisoryFees	4250000	usd
CY2024Q3	irrx	Advisory Fees Charge Percentage AdvisoryFeesChargePercentage	0.0065	pure
	irrx	Number Of Days After The Consummation Of Business Combination For Warrants To Be Exercised NumberOfDaysAfterTheConsummationOfBusinessCombinationForWarrantsToBeExercised	P30D
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	18
CY2024Q3	irrx	Class Of Warrants Or Rights Redemption Price Per Unit ClassOfWarrantsOrRightsRedemptionPricePerUnit	0.01
	irrx	Minimum Notice Period To Be Given To Holders Of Warrants Prior To Redemption MinimumNoticePeriodToBeGivenToHoldersOfWarrantsPriorToRedemption	P30D
	irrx	Common Stocks Threshold Trading Day CommonStocksThresholdTradingDay	P20D
	irrx	Common Stock Threshold Consecutive Trading Day CommonStockThresholdConsecutiveTradingDay	P30D
	irrx	Number Of Trading Days For Determining The Exercise Price Of Warrants NumberOfTradingDaysForDeterminingTheExercisePriceOfWarrants	P10D
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2024Q3	irrx	Percent Of Convertible Share To Outstanding Shares PercentOfConvertibleShareToOutstandingShares	0.20	pure
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd

Files In Submission

Name	View Source	Status
0001213900-25-003482-index-headers.html	Edgar Link	pending
0001213900-25-003482-index.html	Edgar Link	pending
0001213900-25-003482.txt	Edgar Link	pending
0001213900-25-003482-xbrl.zip	Edgar Link	pending
ea0226352-10q_integra.htm	Edgar Link	pending
ea022635201ex10-2_integra.htm	Edgar Link	pending
ea022635201ex31-1_integra.htm	Edgar Link	pending
ea022635201ex31-2_integra.htm	Edgar Link	pending
ea022635201ex32-1_integra.htm	Edgar Link	pending
ea022635201ex32-2_integra.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
irrx-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
irrx-20240930_def.xml	Edgar Link	unprocessable
irrx-20240930_lab.xml	Edgar Link	unprocessable
ea0226352-10q_integra_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
irrx-20240930_cal.xml	Edgar Link	unprocessable
irrx-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRRX
INTEGRATED RAIL & RESOURCES ACQUISITION CORP Stock $irrx

2025 Q1 Form 10-Q Financial Statement

#000121390025003482 Filed on January 14, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRRX INTEGRATED RAIL & RESOURCES ACQUISITION CORP Stock $irrx

2025 Q1 Form 10-Q Financial Statement

#000121390025003482 Filed on January 14, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRRX
INTEGRATED RAIL & RESOURCES ACQUISITION CORP Stock $irrx